Ankündigung • Jun 30
Getein Biotech, Inc to Report First Half, 2026 Results on Aug 27, 2026 Getein Biotech, Inc announced that they will report first half, 2026 results on Aug 27, 2026 Declared Dividend • Jun 15
Dividend of CN¥0.15 announced Shareholders will receive a dividend of CN¥0.15. Ex-date: 18th June 2026 Payment date: 18th June 2026 Dividend yield will be 2.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (52% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 12% per year over the past 8 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 42% to shift the payout ratio to a potentially unsustainable range, which is more than the 8.2% EPS decline seen over the last 5 years. Buy Or Sell Opportunity • May 14
Now 21% undervalued Over the last 90 days, the stock has risen 11% to CN¥9.66. The fair value is estimated to be CN¥12.18, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last 3 years. Earnings per share has declined by 19%. Reported Earnings • May 01
Full year 2025 earnings released: EPS: CN¥0.44 (vs CN¥0.44 in FY 2024) Full year 2025 results: EPS: CN¥0.44 (in line with FY 2024). Revenue: CN¥1.05b (down 9.7% from FY 2024). Net income: CN¥220.7m (down 1.3% from FY 2024). Profit margin: 21% (up from 19% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Ankündigung • Apr 30
Getein Biotech, Inc, Annual General Meeting, May 22, 2026 Getein Biotech, Inc, Annual General Meeting, May 22, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China New Risk • Apr 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.0% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Apr 01
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥10.63, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 42x in the Biotechs industry in China. Total loss to shareholders of 14% over the past three years. Ankündigung • Mar 30
Getein Biotech, Inc to Report Q1, 2026 Results on Apr 30, 2026 Getein Biotech, Inc announced that they will report Q1, 2026 results on Apr 30, 2026 Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥10.38, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 43x in the Biotechs industry in China. Total loss to shareholders of 18% over the past three years. Ankündigung • Dec 26
Getein Biotech, Inc to Report Fiscal Year 2025 Results on Apr 30, 2026 Getein Biotech, Inc announced that they will report fiscal year 2025 results on Apr 30, 2026 Buy Or Sell Opportunity • Nov 21
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 8.3% to CN¥8.10. The fair value is estimated to be CN¥10.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Earnings per share has declined by 38%. Reported Earnings • Oct 31
Third quarter 2025 earnings released: EPS: CN¥0.11 (vs CN¥0.11 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.11 (in line with 3Q 2024). Revenue: CN¥245.0m (down 6.5% from 3Q 2024). Net income: CN¥51.7m (down 6.7% from 3Q 2024). Profit margin: 21% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Ankündigung • Sep 30
Getein Biotech, Inc to Report Q3, 2025 Results on Oct 31, 2025 Getein Biotech, Inc announced that they will report Q3, 2025 results on Oct 31, 2025 Declared Dividend • Sep 11
First half dividend of CN¥0.09 announced Shareholders will receive a dividend of CN¥0.09. Ex-date: 15th September 2025 Payment date: 15th September 2025 Dividend yield will be 2.1%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (50% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 7 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 45% to shift the payout ratio to a potentially unsustainable range, which is more than the 8.0% EPS decline seen over the last 5 years. Board Change • Aug 29
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. 2 independent directors (6 non-independent directors). Independent Director Hua Ling was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Ankündigung • Jun 30
Getein Biotech, Inc to Report First Half, 2025 Results on Aug 30, 2025 Getein Biotech, Inc announced that they will report first half, 2025 results on Aug 30, 2025 Declared Dividend • Jun 13
Dividend of CN¥0.09 announced Shareholders will receive a dividend of CN¥0.09. Ex-date: 17th June 2025 Payment date: 17th June 2025 Dividend yield will be 2.2%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (45% earnings payout ratio) and cash flows (38% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 7 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 50% to shift the payout ratio to a potentially unsustainable range, which is more than the 7.6% EPS decline seen over the last 5 years. Reported Earnings • May 05
Full year 2024 earnings released: EPS: CN¥0.44 (vs CN¥0.55 in FY 2023) Full year 2024 results: EPS: CN¥0.44 (down from CN¥0.55 in FY 2023). Revenue: CN¥1.16b (down 15% from FY 2023). Net income: CN¥223.6m (down 20% from FY 2023). Profit margin: 19% (down from 20% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Ankündigung • Apr 30
Getein Biotech, Inc, Annual General Meeting, May 22, 2025 Getein Biotech, Inc, Annual General Meeting, May 22, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China Buy Or Sell Opportunity • Apr 07
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 1.8% to CN¥7.80. The fair value is estimated to be CN¥9.95, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has declined by 25%. Ankündigung • Mar 28
Getein Biotech, Inc to Report Q1, 2025 Results on Apr 30, 2025 Getein Biotech, Inc announced that they will report Q1, 2025 results on Apr 30, 2025 Buy Or Sell Opportunity • Jan 22
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.9% to CN¥7.88. The fair value is estimated to be CN¥9.95, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has declined by 25%. Buy Or Sell Opportunity • Jan 02
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 9.3% to CN¥8.03. The fair value is estimated to be CN¥10.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has declined by 25%. Ankündigung • Dec 27
Getein Biotech, Inc to Report Fiscal Year 2024 Results on Apr 30, 2025 Getein Biotech, Inc announced that they will report fiscal year 2024 results on Apr 30, 2025 Reported Earnings • Nov 02
Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.11 (down from CN¥0.12 in 3Q 2023). Revenue: CN¥262.2m (down 12% from 3Q 2023). Net income: CN¥55.5m (down 8.1% from 3Q 2023). Profit margin: 21% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Ankündigung • Sep 30
Getein Biotech, Inc to Report Q3, 2024 Results on Oct 31, 2024 Getein Biotech, Inc announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥8.28, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 33x in the Biotechs industry in China. Total loss to shareholders of 32% over the past three years. Declared Dividend • Sep 13
First half dividend reduced to CN¥0.09 Dividend of CN¥0.09 is 10% lower than last year. Ex-date: 19th September 2024 Payment date: 19th September 2024 Dividend yield will be 2.6%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (88% earnings payout ratio) and cash flows (52% cash payout ratio). The dividend has increased by an average of 9.3% per year over the past 6 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 1.8% to shift the payout ratio to a potentially unsustainable range, which is similar to the EPS decline seen over the last 5 years. Buy Or Sell Opportunity • Aug 27
Now 20% overvalued Over the last 90 days, the stock has fallen 16% to CN¥7.46. The fair value is estimated to be CN¥6.19, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 12%. Ankündigung • Jun 28
Getein Biotech, Inc to Report First Half, 2024 Results on Aug 29, 2024 Getein Biotech, Inc announced that they will report first half, 2024 results on Aug 29, 2024 Declared Dividend • Jun 07
Dividend of CN¥0.10 announced Shareholders will receive a dividend of CN¥0.10. Ex-date: 12th June 2024 Payment date: 12th June 2024 Dividend yield will be 2.3%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (88% earnings payout ratio) and cash flows (81% cash payout ratio). The dividend has increased by an average of 9.3% per year over the past 6 years. However, payments have been volatile during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend. Reported Earnings • May 01
Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.98 in FY 2022) Full year 2023 results: EPS: CN¥0.55 (down from CN¥0.98 in FY 2022). Revenue: CN¥1.37b (down 25% from FY 2022). Net income: CN¥279.8m (down 44% from FY 2022). Profit margin: 20% (down from 27% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Ankündigung • May 01
Getein Biotech, Inc, Annual General Meeting, May 22, 2024 Getein Biotech, Inc, Annual General Meeting, May 22, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China Ankündigung • Mar 29
Getein Biotech, Inc to Report Q1, 2024 Results on Apr 27, 2024 Getein Biotech, Inc announced that they will report Q1, 2024 results on Apr 27, 2024 Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥7.73, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 30x in the Biotechs industry in China. Total loss to shareholders of 46% over the past three years. Ankündigung • Dec 29
Getein Biotech, Inc to Report Fiscal Year 2023 Results on Apr 27, 2024 Getein Biotech, Inc announced that they will report fiscal year 2023 results on Apr 27, 2024 Reported Earnings • Oct 29
Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.28 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.12 (down from CN¥0.28 in 3Q 2022). Revenue: CN¥297.6m (down 26% from 3Q 2022). Net income: CN¥60.3m (down 59% from 3Q 2022). Profit margin: 20% (down from 36% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Board Change • Oct 10
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. 1 highly experienced director. Chairman of the Supervisory Board Jing Li is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Buying Opportunity • Sep 08
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be CN¥13.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 15%. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.22 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.091 (down from CN¥0.22 in 2Q 2022). Revenue: CN¥319.0m (down 21% from 2Q 2022). Net income: CN¥47.2m (down 57% from 2Q 2022). Profit margin: 15% (down from 28% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Ankündigung • Jun 28
Getein Biotech, Inc to Report First Half, 2023 Results on Aug 29, 2023 Getein Biotech, Inc announced that they will report first half, 2023 results on Aug 29, 2023 Buying Opportunity • Apr 02
Now 21% undervalued Over the last 90 days, the stock is up 7.3%. The fair value is estimated to be CN¥17.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 24%. Reported Earnings • Apr 01
Full year 2022 earnings released: EPS: CN¥0.97 (vs CN¥0.79 in FY 2021) Full year 2022 results: EPS: CN¥0.97 (up from CN¥0.79 in FY 2021). Revenue: CN¥1.82b (up 30% from FY 2021). Net income: CN¥492.8m (up 24% from FY 2021). Profit margin: 27% (down from 28% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥15.22, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 39x in the Biotechs industry in China. Total returns to shareholders of 36% over the past three years. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.16 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.28 (up from CN¥0.16 in 3Q 2021). Revenue: CN¥404.0m (up 26% from 3Q 2021). Net income: CN¥145.4m (up 77% from 3Q 2021). Profit margin: 36% (up from 26% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 27
Second quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.22. Revenue: CN¥402.5m (up 24% from 2Q 2021). Net income: CN¥111.1m (up 2.7% from 2Q 2021). Profit margin: 28% (down from 33% in 2Q 2021). The decrease in margin was driven by higher expenses. Reported Earnings • Apr 28
Full year 2021 earnings released: EPS: CN¥1.10 (vs CN¥0.84 in FY 2020) Full year 2021 results: EPS: CN¥1.10 (up from CN¥0.84 in FY 2020). Revenue: CN¥1.40b (up 25% from FY 2020). Net income: CN¥399.0m (up 31% from FY 2020). Profit margin: 28% (up from 27% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 14
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: CN¥1.08 (up from CN¥0.84 in FY 2020). Revenue: CN¥1.37b (up 22% from FY 2020). Net income: CN¥392.1m (up 29% from FY 2020). Profit margin: 29% (up from 27% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 8.9%. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥20.72, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 48x in the Biotechs industry in China. Total returns to shareholders of 36% over the past three years. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.27 in 3Q 2020) The company reported a poor third quarter result with weaker earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: CN¥321.9m (down 16% from 3Q 2020). Net income: CN¥82.3m (down 19% from 3Q 2020). Profit margin: 26% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥324.3m (up 40% from 2Q 2020). Net income: CN¥108.2m (up 105% from 2Q 2020). Profit margin: 33% (up from 23% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥22.69, the stock trades at a trailing P/E ratio of 23.1x. Average forward P/E is 46x in the Biotechs industry in China. Total returns to shareholders of 12% over the past three years. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.12 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥276.0m (up 86% from 1Q 2020). Net income: CN¥62.7m (up 45% from 1Q 2020). Profit margin: 23% (down from 29% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 05
Full year 2020 earnings released: EPS CN¥1.20 (vs CN¥1.31 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: CN¥1.13b (up 17% from FY 2019). Net income: CN¥311.9m (down 8.2% from FY 2019). Profit margin: 28% (down from 35% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Jan 29
New 90-day low: CN¥30.30 The company is down 21% from its price of CN¥38.50 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥30.80 The company is down 17% from its price of CN¥36.95 on 29 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Nov 24
New 90-day low: CN¥34.80 The company is down 4.0% from its price of CN¥36.13 on 26 August 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥337.9m, up 26% from the prior year. Total revenue was CN¥1.10b over the last 12 months, up 27% from the prior year. Is New 90 Day High Low • Oct 22
New 90-day high: CN¥41.89 The company is up 9.0% from its price of CN¥38.40 on 24 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. Ankündigung • Jul 30
Getein Biotech, Inc (SHSE:603387) completed the acquisition of 54.96% stake in Wuhan King Diagnostic Technology Co.,Ltd. from a group of 21 sellers. Getein Biotech, Inc (SHSE:603387) entered into a share transfer agreement to acquire 54.96% stake in Wuhan King Diagnostic Technology Co.,Ltd. from a group of 21 sellers for CNY 63.9 million on March 18, 2020. The consideration will be paid in cash to acquire 12,658,621 shares of Wuhan King Diagnostic Technology. After the share transfer is completed Getein Biotech plans to subscribe for the target company’s new shares at a price of CNY 3.42 per share, the subscription amount is CNY 10 million. On completion of this transaction, Getein Biotech will hold 58.53% stake in Wuhan King Diagnostic Technology. This transaction is subject to the completion of the transfer registration procedures of the China Securities Depository and Clearing Corporation Limited. The transaction was reviewed and approved by shareholders of Wuhan King Diagnostic Technology and the 21st meeting of the Getein Biotech's second directorate held on March 18, 2020. The transaction doesn’t need to be approved by the shareholders of Getein Biotech.
Getein Biotech, Inc (SHSE:603387) completed the acquisition of 54.96% stake in Wuhan King Diagnostic Technology Co.,Ltd. from a group of 21 sellers on July 21, 2020. Ankündigung • Jul 10
Getein Biotech, Inc to Report First Half, 2020 Results on Aug 27, 2020 Getein Biotech, Inc announced that they will report first half, 2020 results on Aug 27, 2020 
